Glucagonoma Syndrome


Article Author:
Sartaj Sandhu


Article Editor:
Ishwarlal Jialal


Editors In Chief:
Kranthi Sitammagari
Mayank Singhal


Managing Editors:
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Frank Smeeks
Kristina Soman-Faulkner
Benjamin Eovaldi
Radia Jamil
Sobhan Daneshfar
Saad Nazir
William Gossman
Pritesh Sheth
Hassam Zulfiqar
Navid Mahabadi
Steve Bhimji
John Shell
Matthew Varacallo
Ahmad Malik
Mark Pellegrini
James Hughes
Beata Beatty
Hajira Basit
Phillip Hynes


Updated:
6/4/2019 2:40:23 PM

Introduction

Glucagonomas are neuroendocrine tumors of the pancreatic islets that secrete glucagon. Glucagonoma syndrome occurs due to the effects of elevated glucagon levels secreted by the tumor. The first case was described in 1942 by Becker et al. in a 45-year-old woman presenting with widespread dermatitis, weight loss, glossitis, and abnormal glucose tolerance associated with an islet cell neoplasm of the pancreas on autopsy specimen[1]. IN 1966, McGavran and colleagues identified the classic symptoms of mild diabetes and dermatitis along with elevated glucagon levels related to a metastatic alpha cell tumor of the pancreatic islets[2]. This review highlights the clinical presentation and management of glucagonomas.

Etiology

Glucagonomas are neuroendocrine tumors originating from multipotential stem cells of endodermal origin. They arise from the alpha cells of the islets in the pancreas. Most glucagonomas are solitary. However, less than 10% of them have been associated with multiple endocrine neoplasia 1 syndrome (MEN1)[3].

Epidemiology

Glucagonomas are sporadic and rare. The annual occurrence is 0.01 to 0.1 new cases per 100,000[4]. They are typically large (greater than 3 cm) and located mainly in the tail or the body of the pancreas due to the high prevalence of alpha cells in this area. Over 50% are metastatic at the time of diagnosis. The incidence of glucagonoma in males and females is similar. Most patients with glucagonoma present in the fifth to sixth decade of life.

Pathophysiology

Glucagon is a single-chain polypeptide made up of 29 amino acids that are derived from a larger precursor peptide, which is cleaved upon secretion. The main site of glucagon production is pancreatic alpha-islet cells, which secrete glucagon in response to hypoglycemia, amino acids, gastric inhibitory peptide, and ghrelin. Glucagon acts in the liver to increase glycogenolysis and gluconeogenesis by stimulating the cAMP pathway resulting in an elevation of plasma glucose. The secretion of glucagon is inhibited by hyperglycemia, insulin, somatostatin, and GLP-1[5]. It also causes relaxation of the smooth muscle of the stomach, duodenum, small bowel, and colon. The other actions of glucagon include stimulation of lipolysis.

Excessive secretion of glucagon from the tumor leads to the glucagonoma syndrome. Classic glucagonoma syndrome consists of weight loss, necrolytic migratory erythema (NME), diabetes, and mucosal abnormalities including stomatitis, cheilitis, and glossitis[6]. The precise etiology of NME is not known, but it is thought secondary to a combination of poor nutrition, low zinc, and amino acid levels. Diabetes results secondary to the direct effects of glucagon. Diarrhea may occur from increased glucagon levels and co-secretion of gastrin, VIP, serotonin, or calcitonin.

History and Physical

Glucagonoma syndrome also goes by the acronym 4D syndrome, consisting of dermatosis, diabetes, deep vein thrombosis, and depression[7].

  • The dermatoses associated with glucagonoma syndrome is called necrolytic migratory erythema (NME). It was first described by Wilkinson[8]. It is present in up to 90% of the patients. It is widespread, with main areas of involvement being perioral, perigenital regions and the extremities. NME often starts as pruritic and painful erythematic papules or plaques which gradually enlarge and coalesce to form bullous lesions. Mucosal involvement presents in the form of angular cheilitis, glossitis, stomatitis, and blepharitis[9]. Patients may also have hair loss and nail dystrophy.
  • Weight loss occurs in about 90% of the patients with glucagonoma syndrome and is also one of the presenting features.
  • Diabetes mellitus is present in nearly 80% of the patients. It is mostly mild as beta cell function of the pancreas is preserved and hence the production of insulin-mitigating ketoacidosis.
  • Deep vein thrombosis is noted in nearly 50% of the patients. Patients with the unexplained thromboembolic disease should undergo a thorough history, physical and evaluation for the possibility of glucagonoma. It can occasionally present as pulmonary embolism which can be fatal.
  • Depression, occurring in about 50% of the patients, may be related to the chronic dermatosis. Other neuropsychiatric manifestations include dementia, psychosis, agitation, hyperreflexia, ataxia, paranoid delusions, and proximal muscle weakness.
  • Chronic diarrhea is seen in about 30% of the patients with glucagonoma syndrome.

Evaluation

Glucagonoma should be suspected in patients with NME associated with or without the other symptoms discussed above.

  • A fasting plasma glucagon level should be drawn. Fasting plasma glucagon levels are abnormally elevated usually greater than 500 pg/mL. Normal fasting plasma glucagon levels are less than 150 pg/mL. It is important to note that different glucagon assays may exhibit variable cross-reactivity with different isoforms of glucagon, not all of which (nearly 70%) are biologically active. Serial measurements should, therefore, always be performed using the same assay directed against the C-terminus.
  • Serum concentrations of amino acids and zinc should be checked to evaluate the nutritional status. The laboratory abnormalities with glucagonoma can include hypoaminoacidemia (due to targeting of amino acids into metabolic pathways in the liver by excessive hyperglucagonemia) and low zinc levels.
  • A complete blood count (CBC) should be obtained to check for concurrent normocytic anemia. A comprehensive metabolic panel (CMP) should be checked to detect other metabolic abnormalities.
  • Obtaining serum parathyroid hormone, gastrin, insulin, pancreatic polypeptide, serotonin, vasoactive intestinal polypeptide (VIP), prolactin and ACTH levels is important as glucagonoma can rarely be associated with the MEN1 syndrome.
  • Skin biopsy of the NME lesion shows small bullae consisting of acantholytic epidermal cells along with lymphocytic and neutrophilic infiltrate. The dermis contains a perivascular lymphocytic infiltrate with an intact epidermis.

Imaging Studies

Tumor localization is typically started with a helical multiphasic contrast-enhanced CT scan.  The sensitivity of multiphasic CT scans is significantly high at greater than 80% for detecting intrapancreatic neuroendocrine tumors.

MRI is performed in case of indeterminate lesions and may have a better sensitivity to detect liver metastases.

Glucagonomas express abundant somatostatin receptors as compared to other pancreatic neuroendocrine tumors. Hence, they are suitable for localization using somatostatin analogues like octreotide. Somatostatin receptor scintigraphy (SRS) was positive in 97% of glucagonoma patients, as noted in a study by Kindmark et al.[10]. It also has the advantage of detecting small, occult metastases within and outside of the abdomen and hence, helpful in the staging of the tumor.

Functional PET imaging technique with DOTA peptides like DOTATATE, DOTANOC, DOTATOC could be used in the localization of non-metastatic tumors. They offer higher spatial resolution as compared to the SRS and provide higher sensitivity, particularly in the detection of smaller lesions.

Treatment / Management

Initial Management

  • Surgical resection is the only curative option in a minority of cases where the tumor is localized at the time of diagnosis[11]. The type of pancreatic resection is determined after careful assessment of the site and size of the tumor.
  • Nutritional support includes total parenteral nutrition, supplementation of amino acids and zinc supplementation to reverse the effects of malnutrition and catabolic effects of weight loss from the glucagon.
  • Antibiotics, zinc replacement, and steroids may help with the improvement of NME. 
  • Somatostatin analogs like octreotide and lanreotide help to reverse the effects of glucagon excess as well as inhibit secretion of glucagon [12]. Octreotide LAR and Lanreotide have been reported to significantly lengthen the time to tumor progression[13],[14]. It also improves NME, diabetes, diarrhea, and neurological symptoms.
  • Prophylactic anticoagulant therapy, for example, heparin to prevent deep venous thrombosis is mandatory for all patients during the perioperative period.

Management of progressive/Metastatic Disease

The most common site of metastasis is liver. Hepatic resection has been recommended in patients without widespread liver involvement, diffuse extrahepatic metastases, and decreased liver function[15]. Resection has led to a decrease in glucagon levels and significant improvement of NME.

Hepatic arterial embolization with or without selective hepatic artery infusion of chemotherapy is a palliative method used in patients with symptomatic hepatic metastases and are not candidates for hepatic resection[16].

Radiofrequency ablation applies to smaller lesions (typically smaller than 3 cm) and is less invasive than hepatic resection or hepatic arterial embolization. It can be used as in conjunction with surgical resection, or as a primary treatment technique for the hepatic metastases[17].

Combination chemotherapy with streptozocin, 5-fluorouracil or Temozolomide containing regimens, often in combination with a somatostatin analog have been used in patients with large tumors and enlarging metastases. The use of systemic chemotherapy is limited to patients with advanced disease[18].

Molecular targeted agents such as sunitinib, a tyrosine kinase inhibitor, and everolimus, a mTOR inhibitor are approved in the United States for treatment of advanced, well-differentiated, pancreatic neuroendocrine tumors including glucagonomas[19],[20].

Peptide receptor radionuclide therapy (PRRT), also known as radioisotope therapy, is a novel method being used for the management of neuroendocrine tumors. The high expression of somatostatin receptors in glucagonoma provides an opportunity for the use of PRRT[21].

Differential Diagnosis

  • Fasting plasma glucagon levels may be elevated in other conditions like acute trauma, diabetes mellitus, burn injury, sepsis, renal failure,  cirrhosis, pancreatitis or Cushing syndrome. Though the fasting plasma glucagon levels in these conditions are elevated, it is typically less than 500 pg/mL. A rare disorder due to an inactivation mutations defect in the glucagon receptor gene that causes pancreatic alpha cell hyperplasia, an elevation of glucagon without symptoms is called Mahvash disease[22].
  • NME is not specific to glucagonoma and can also be seen in with chronic liver disease, inflammatory bowel disease, pancreatitis, heroin abuse, jejunal and rectal adenocarcinoma, and myelodysplastic syndrome.
  • NME-like lesions have been associated with essential fatty acid deficiency, zinc deficiency (acrodermatitis enteropathica), and the dermatosis of protein-calorie malnutrition.

Prognosis

Glucagonomas are typically slow growing; however, they are usually advanced by the time of diagnosis. The predictors of survival are dependent on age, tumor grade, and distant metastases. The cure is rarely achieved once the tumor is metastatic.

As per the National Comprehensive Cancer Network guidelines, the post-resection follow up includes history and physical examination, serum glucagon level, CT or MRI in the initial 3 to 12-month period.  After 1 year, it is recommended to follow the same measures every 6 to 12 months up to a maximum of 10 years.

Enhancing Healthcare Team Outcomes

Glucagonoma syndrome is difficult to diagnose and once diagnosed a challenge to manage. An interprofessional team of nurses, primary care providers, and specialists must work together to monitor the patient as they are at risk for developing dermatosis, diabetes, deep vein thrombosis, and depression. [Level V]


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Glucagonoma Syndrome - Questions

Take a quiz of the questions on this article.

Take Quiz
Select the condition associated with necrolytic migratory erythema.



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 55-year-old lady presented with diffuse, painful rash of 6 months duration present over her extremities, around her mouth and genitalia. Further questioning revealed she had lost 20 pounds over the past six months. She has on and off diarrhea for about a year. On exam, she was noted to have diffuse ulcerated plaque-like weeping rash present on multiple areas of her body. Blood work showed fasting blood glucose of 142 mg/dl (normal 65-99) and hemoglobin 10.1 g/dl (normal 11.5-15.3). Which of the following blood test should be drawn next to confirm the suspected diagnosis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following is not associated with the glucagonoma syndrome?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which trace mineral deficiency can be seen with glucagonoma syndrome?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Select the true statement about glucagonomas.



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Glucagonoma Syndrome - References

References

Braverman IM,     [PubMed]
McGavran MH,Unger RH,Recant L,Polk HC,Kilo C,Levin ME, A glucagon-secreting alpha-cell carcinoma of the pancreas. The New England journal of medicine. 1966 Jun 23     [PubMed]
Jensen RT,Cadiot G,Brandi ML,de Herder WW,Kaltsas G,Komminoth P,Scoazec JY,Salazar R,Sauvanet A,Kianmanesh R, ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012     [PubMed]
Vinik A,Pacak K,Feliberti E,Perry RR, Glucagonoma Syndrome null. 2000     [PubMed]
Wilkinson DS, Necrolytic migratory erythema with pancreatic carcinoma. Proceedings of the Royal Society of Medicine. 1971 Dec     [PubMed]
Tolliver S,Graham J,Kaffenberger BH, A review of cutaneous manifestations within glucagonoma syndrome: necrolytic migratory erythema. International journal of dermatology. 2018 Jun     [PubMed]
Kindmark H,Sundin A,Granberg D,Dunder K,Skogseid B,Janson ET,Welin S,Oberg K,Eriksson B, Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years. Medical oncology (Northwood, London, England). 2007     [PubMed]
Partelli S,Bartsch DK,Capdevila J,Chen J,Knigge U,Niederle B,Nieveen van Dijkum EJM,Pape UF,Pascher A,Ramage J,Reed N,Ruszniewski P,Scoazec JY,Toumpanakis C,Kianmanesh R,Falconi M, ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. Neuroendocrinology. 2017     [PubMed]
Grozinsky-Glasberg S,Shimon I,Korbonits M,Grossman AB, Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocrine-related cancer. 2008 Sep     [PubMed]
Rinke A,Wittenberg M,Schade-Brittinger C,Aminossadati B,Ronicke E,Gress TM,Müller HH,Arnold R, Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival. Neuroendocrinology. 2017     [PubMed]
McEntee GP,Nagorney DM,Kvols LK,Moertel CG,Grant CS, Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990 Dec     [PubMed]
Kennedy AS, Hepatic-directed Therapies in Patients with Neuroendocrine Tumors. Hematology/oncology clinics of North America. 2016 Feb     [PubMed]
King J,Quinn R,Glenn DM,Janssen J,Tong D,Liaw W,Morris DL, Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008 Sep 1     [PubMed]
Pavel M,Valle JW,Eriksson B,Rinke A,Caplin M,Chen J,Costa F,Falkerby J,Fazio N,Gorbounova V,de Herder W,Kulke M,Lombard-Bohas C,O'Connor J,Sorbye H,Garcia-Carbonero R, ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. Neuroendocrinology. 2017     [PubMed]
Raymond E,Dahan L,Raoul JL,Bang YJ,Borbath I,Lombard-Bohas C,Valle J,Metrakos P,Smith D,Vinik A,Chen JS,Hörsch D,Hammel P,Wiedenmann B,Van Cutsem E,Patyna S,Lu DR,Blanckmeister C,Chao R,Ruszniewski P, Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. The New England journal of medicine. 2011 Feb 10     [PubMed]
Yao JC,Shah MH,Ito T,Bohas CL,Wolin EM,Van Cutsem E,Hobday TJ,Okusaka T,Capdevila J,de Vries EG,Tomassetti P,Pavel ME,Hoosen S,Haas T,Lincy J,Lebwohl D,Öberg K, Everolimus for advanced pancreatic neuroendocrine tumors. The New England journal of medicine. 2011 Feb 10     [PubMed]
Kwekkeboom DJ,Bakker WH,Kam BL,Teunissen JJ,Kooij PP,de Herder WW,Feelders RA,van Eijck CH,de Jong M,Srinivasan A,Erion JL,Krenning EP, Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. European journal of nuclear medicine and molecular imaging. 2003 Mar     [PubMed]
Wewer Albrechtsen NJ,Kuhre RE,Pedersen J,Knop FK,Holst JJ, The biology of glucagon and the consequences of hyperglucagonemia. Biomarkers in medicine. 2016 Nov     [PubMed]
Ro C,Chai W,Yu VE,Yu R, Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment. Chinese journal of cancer. 2013 Jun     [PubMed]
Ito T,Igarashi H,Jensen RT, Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. Best practice     [PubMed]
Caplin ME,Pavel M,Ruszniewski P, Lanreotide in metastatic enteropancreatic neuroendocrine tumors. The New England journal of medicine. 2014 Oct 16     [PubMed]
Wermers RA,Fatourechi V,Wynne AG,Kvols LK,Lloyd RV, The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine. 1996 Mar     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of PA-Hospital Medicine. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for PA-Hospital Medicine, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in PA-Hospital Medicine, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of PA-Hospital Medicine. When it is time for the PA-Hospital Medicine board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study PA-Hospital Medicine.